Lilly to begin pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19 in New Mexico

Study will provide real-world data and insight on various infusion setting experiences Plan to study bamlanivimab in a diverse group of participants, including Native American communities INDIANAPOLIS , Dec. 18, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) today announced plans to begin